The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: Insights from type II diabetes

Annual Review of Biophysics

Volumn 38, Issue 1, 2009, Pages 125-152

  Hebda, James A ^a   Miranker, Andrew D ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

synuclein; A ; Amylin; IAPP; Mechanism; Protein folding

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; LYSOZYME; PREALBUMIN;

ALPHA HELIX; ALZHEIMER DISEASE; ATOMIC FORCE MICROSCOPY; BETA SHEET; CATALYSIS; CONFORMATION; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; ELECTRON MICROSCOPY; ENZYME MECHANISM; HOMEOSTASIS; HUMAN; KINETICS; LIPID BILAYER; MEMBRANE STRUCTURE; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PRECURSOR; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SURFACE PROPERTY; ANIMAL; BIOLOGICAL MODEL; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; ULTRASTRUCTURE;

AMYLOID BETA-PROTEIN; ANIMALS; CATALYSIS; DIABETES MELLITUS, TYPE 2; HUMANS; LIPID BILAYERS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67650325176     PISSN: 1936122X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.biophys.050708.133622     Document Type: Review

References (170)

1. Abedini A, Meng F, Raleigh DP. 2007. A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J. Am. Chem. Soc. 129:11300-11301 (Pubitemid 47555526)
2. Apostolidou M, Jayasinghe SA, Langen R. 2008. Structure of alpha-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding. J. Biol. Chem. 283:17205-17210
3. Arispe N, Pollard HB, Rojas E. 1994. The ability of amyloid beta-protein [A beta P (1-40)] to form Ca2+ channels provides a mechanism for neuronal death in Alzheimer's disease. Ann. N. Y. Acad. Sci. 747:256-266
4. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008. Adapting proteostasis for disease intervention. Science 319:916-919
5. Baldwin TO, Ziegler MM, Chaffotte AF, Goldberg ME. 1993. Contribution of folding steps involving the individual subunits of bacterial luciferase to the assembly of the active heterodimeric enzyme. J. Biol. Chem. 268:10766-10772 (Pubitemid 23162252)
6. Barnhart MM, Chapman MR. 2006. Curli biogenesis and function. Annu. Rev. Microbiol. 60:131-147
7. Beyer K. 2007. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem. Biophys. 47:285-299 (Pubitemid 47338366)
8. Bezprozvanny I, Mattson MP. 2008. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 31:454-463
9. Bisaglia M,Tessari I, Pinato L, Bellanda M, Giraudo S, et al. 2005. A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles. Biochemistry 44:329-339 (Pubitemid 40095735)
10. Blennow K, de Leon MJ, Zetterberg H. 2006. Alzheimer's disease. Lancet 368:387-403
11. Bokvist M, Grobner G. 2007. Misfolding of amyloidogenic proteins at membrane surfaces: the impact of macromolecular crowding. J. Am. Chem. Soc. 129:14848-14849
12. Bokvist M, Lindstrom F, Watts A, Grobner G. 2004. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J. Mol. Biol. 335:1039-1049 (Pubitemid 38091609)
13. Brender JR, Lee EL, Cavitt MA, Gafni A, Steel DG, Ramamoorthy A. 2008. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2- diabetes-related peptide. J. Am. Chem. Soc. 130:6424-6429 (Pubitemid 351706103)
14. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250
15. Brouwers N, Sleegers K,Van Broeckhoven C. 2008. Molecular genetics of Alzheimer's disease: an update. Ann. Med. 18:1-22
16. Bussell R Jr, Eliezer D. 2003. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 329:763-778 (Pubitemid 36629369)
17. Chandra S, Chen X, Rizo J, Jahn R, Sudhof TC. 2003. A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem. 278:15313-15318
18. Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, et al. 2002. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295:851-855 (Pubitemid 34118365)
19. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169
20. Chen Y, Ding F, Nie H, Serohijos AW, Sharma S, et al. 2008. Protein folding: then and now. Arch. Biochem. Biophys. 469:4-19
21. Cherny I, Gazit E. 2008. Amyloids: not only pathological agents but also ordered nanomaterials. Angew. Chem. Int. Ed. Engl. 47:4062-4069
22. Chi EY, Ege C,Winans A, Majewski J,Wu G, et al. 2008. Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide. Proteins 72:1-24
23. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. 1997. Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272:22987-22990
24. Chua CE, Tang BL. 2006. Alpha-synuclein and Parkinson's disease: the first roadblock. J. Cell Mol. Med. 10:837-846
25. Clark A, Nilsson MR. 2004. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia 47:157-169 (Pubitemid 38315352)
26. Cole SL, Vassar R. 2008. The role of APP processing by BACE1, the beta-secretase, in Alzheimer's disease pathophysiology. J. Biol. Chem. 283:29621-29625
27. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ. 1998. Solution structure of amyloid beta-peptide( 1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 37:11064-11077 (Pubitemid 28368933)
28. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, et al. 2006. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313:324-328 (Pubitemid 44480951)
29. Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, et al. 2002. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur. J. Biochem. 269:5642-5648 (Pubitemid 35365553)
30. Danielsson J, Andersson A, Jarvet J, Graslund A. 2006. 15N relaxation study of the amyloid beta-peptide: structural propensities and persistence length. Magn. Reson. Chem. 44(Spec. No.):S114-21
31. De Simone A, Esposito L, Pedone C, Vitagliano L. 2008. Insights into stability and toxicity of amyloidlike oligomers by replica exchange molecular dynamics analyses. Biophys. J. 95:1965-1973
32. Diaz GB, Cortizo AM, Garcia ME, Gagliardino JJ. 1988. Lipid composition of normal male rat islets. Lipids 23:1125-1128
33. Dickson DW. 1997. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56:321-339
34. Domanov YA, Kinnunen PK. 2008. Islet amyloid polypeptide forms rigid lipid-protein amyloid fibrils on supported phospholipid bilayers. J. Mol. Biol. 376:42-54
35. Drescher M, Veldhuis G, van Rooijen BD, Milikisyants S, Subramaniam V, Huber M. 2008. Antiparallel arrangement of the helices of vesicle-bound alpha-synuclein. J. Am. Chem. Soc. 130:7796-7797 (Pubitemid 351875034)
36. Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, et al. 2003. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424:783-788 (Pubitemid 37021708)
37. El-Agnaf OM, Irvine GB. 2000. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 130:300-309
38. Eliezer D, Kutluay E, Bussell R Jr, Browne G. 2001. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307:1061-1073 (Pubitemid 33029953)
39. Engel MF, Khemtemourian L, Kleijer CC, Meeldijk HJ, Jacobs J, et al. 2008. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc. Natl. Acad. Sci. USA 105:6033-6038 (Pubitemid 351758394)
40. Engel MF, Yigittop H, Elgersma RC, Rijkers DT, Liskamp RM, et al. 2006. Islet amyloid polypeptide inserts into phospholipid monolayers as monomer. J. Mol. Biol. 356:783-789 (Pubitemid 43139337)
41. Engelman DM, Chen Y, Chin CN, Curran AR, Dixon AM, et al. 2003. Membrane protein folding: beyond the two stage model. FEBS Lett. 555:122-125 (Pubitemid 37431108)
42. Fahn S. 2003. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991:1-14 (Pubitemid 36793796)
43. Fawzi NL, Kohlstedt KL, Okabe Y, Head-Gordon T. 2008. Protofibril assemblies of the Arctic, Dutch, and Flemish mutants of the Alzheimer's Abeta1-40 peptide. Biophys. J. 94:2007-2016
44. Findeis MA,Musso GM, Arico-Muendel CC, Benjamin HW, Hundal AM, et al. 1999. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 38:6791-6800 (Pubitemid 129514980)
45. Finder VH, Glockshuber R. 2007. Amyloid-beta aggregation. Neurodegener. Dis. 4:13-27
46. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, et al. 2001. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029 (Pubitemid 32374532)
47. Fink AL. 2006. The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res. 39:628-634
48. Flamia R, Salvi AM, D'Alessio L, Castle JE, Tamburro AM. 2007. Transformation of amyloid-like fibers, formed from an elastin-based biopolymer, into a hydrogel: an X-ray photoelectron spectroscopy and atomic force microscopy study. Biomacromolecules 8:128-138 (Pubitemid 46140483)
49. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. 2004. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24:6715-6723
50. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. 2006. Functional amyloid formation within mammalian tissue. PLoS Biol. 4:e6
51. Fowler DM, Koulov AV, Balch WE, Kelly JW. 2007. Functional amyloid-from bacteria to humans. Trends Biochem. Sci. 32:217-224
52. Frieden C. 2007. Protein aggregation processes: in search of the mechanism. Protein Sci. 16:2334-2344
53. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH. 2000. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 166:324-333
54. Gazit E. 2007. Self-assembled peptide nanostructures: the design of molecular building blocks and their technological utilization. Chem. Soc. Rev. 36:1263-1269
55. George JM, Jin H,Woods WS, Clayton DF. 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361-372
56. Glabe CG. 2006. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27:570-575
57. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, et al. 2003. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100:10417-10422 (Pubitemid 37071893)
58. Green JD, Kreplak L, Goldsbury C, Li Blatter X, Stolz M, et al. 2004. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J. Mol. Biol. 342:877-887 (Pubitemid 39165656)
59. Haataja L, Gurlo T, Huang CJ, Butler PC. 2008. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 29:303-316 (Pubitemid 351679701)
60. Haber E, Anfinsen CB. 1962. Side-chain interactions governing the pairing of half-cystine residues in ribonuclease. J. Biol. Chem. 237:1839-1844
61. Halliday GM, McCann H. 2008. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms. Exp. Neurol. 209:12-21
62. Heinitz K, Beck M, Schliebs R, Perez-Polo JR. 2006. Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells. J. Neurochem. 98:1930-1945 (Pubitemid 44298256)
63. Hiddinga HJ, Eberhardt NL. 1999. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am. J. Pathol. 154:1077-1088
64. Hoppener JW, Ahren B, Lips CJ. 2000. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343:411-419 (Pubitemid 30626125)
65. Huang CJ, Haataja L, Gurlo T, Butler AE, Wu X, et al. 2007. Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am. J. Physiol. Endocrinol. Metab. 293:E1656-62
66. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, et al. 2007. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56:2016-2027 (Pubitemid 47201819)
67. Huang HW, Chen FY, Lee MT. 2004. Molecular mechanism of peptide-induced pores in membranes. Phys. Rev. Lett. 92:198304
68. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. 2004. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. N. Y. Acad. Sci. 1012:153-163 (Pubitemid 38453522)
69. Hubbard JA, Martin SR, Chaplin LC, Bose C, Kelly SM, Price NC. 1991. Solution structures of calcitonin-gene-related-peptide analogues of calcitonin-gene-related peptide and amylin. Biochem. J. 275(Pt. 3):785-788
70. Hull RL,Westermark GT,Westermark P, Kahn SE. 2004. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89:3629-3643
71. Jaikaran ET, Clark A. 2001. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim. Biophys. Acta 1537:179-203 (Pubitemid 33139801)
72. Jaikaran ET, Higham CE, Serpell LC, Zurdo J, Gross M, et al. 2001. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308:515-525 (Pubitemid 33027616)
73. Jan A, Gokce O, Luthi-Carter R, Lashuel HA. 2008. The ratio of monomeric to aggregated forms of Abeta 40 and Abeta 42 is an important determinant of Abeta aggregation, fibrillogenesis, and toxicity. J. Biol. Chem. 283:28176-28189
74. Jang H, Zheng J, Lal R, Nussinov R. 2008. New structures help the modeling of toxic amyloidbeta ion channels. Trends Biochem. Sci. 33:91-100
75. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. 1999. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491-498 (Pubitemid 29106861)
76. Jao CC, Der-Sarkissian A, Chen J, Langen R. 2004. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. USA 101:8331-8336 (Pubitemid 38736575)
77. Jarvet J, Danielsson J, Damberg P, Oleszczuk M, Graslund A. 2007. Positioning of the Alzheimer Abeta(1-40) peptide in SDS micelles using NMR and paramagnetic probes. J. Biomol. NMR 39:63-72 (Pubitemid 47249695)
78. Jayasinghe SA, Langen R. 2005. Lipid membranes modulate the structure of islet amyloid polypeptide. Biochemistry 44:12113-12119 (Pubitemid 41285709)
79. Ji SR, Wu Y, Sui SF. 2002. Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. J. Biol. Chem. 277:6273-6279 (Pubitemid 34975653)
80. Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR. 2002. The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. USA 99:9196-9201 (Pubitemid 34764590)
81. Joh NH, Min A, Faham S, Whitelegge JP, Yang D, et al. 2008. Modest stabilization by most hydrogenbonded side-chain interactions in membrane proteins. Nature 453:1266-1270 (Pubitemid 351913594)
82. Johnson SM,Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. 2005. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38:911-921
83. Kahn SE, Andrikopoulos S, Verchere CB. 1999. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253 (Pubitemid 29061094)
84. Kapurniotu A. 2001. Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Biopolymers 60:438-459 (Pubitemid 35000911)
85. Kapurniotu A, Schmauder A, Tenidis K. 2002. Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J. Mol. Biol. 315:339-350 (Pubitemid 34729344)
86. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489 (Pubitemid 36444329)
87. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, et al. 2004. Permeabilization of lipid bilayers is acommonconformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279:46363-46366 (Pubitemid 39518276)
88. Killian JA, Nyholm TK. 2006. Peptides in lipid bilayers: the power of simple models. Curr. Opin. Struct. Biol. 16:473-479 (Pubitemid 44149068)
89. Kirkitadze MD, Condron MM, Teplow DB. 2001. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J. Mol. Biol. 312:1103-1119
90. Knight JD, Hebda JA, Miranker AD. 2006. Conserved and cooperative assembly of membrane-bound alpha-helical states of islet amyloid polypeptide. Biochemistry 45:9496-9508
91. Knight JD, Miranker AD. 2004. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 341:1175-1187
92. Knight JD,Williamson JA, Miranker AD. 2008. Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin. Protein Sci. 17:1850-1856
93. Koo BW, Hebda JA, Miranker AD. 2008. Amide inequivalence in the fibrillar assembly of islet amyloid polypeptide. Protein Eng. Des. Sel. 21:147-154
94. Koo BW,Miranker AD. 2005. Contribution of the intrinsic disulfide to the assembly mechanism of islet amyloid. Protein Sci. 14:231-239
95. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, et al. 2005. A combinatorial code for the interaction of alpha-synuclein with membranes. J. Biol. Chem. 280:31664-31672 (Pubitemid 41291913)
96. Kudva YC, Mueske C, Butler PC, Eberhardt NL. 1998. A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. Biochem. J. 331(Pt. 3):809-813 (Pubitemid 28211903)
97. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. 2001. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79:595-605 (Pubitemid 33029933)
98. Larson JL, Miranker AD. 2004. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol. 335:221-231
99. Lashuel HA, Lansbury PT Jr. 2006. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39:167-201
100. Lin CY, Gurlo T, Kayed R, Butler AE, Haataja L, et al. 2007. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes 56:1324-1332
101. Lin H, Bhatia R, Lal R. 2001. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 15:2433-2444 (Pubitemid 33063171)
102. Lopes DH, Meister A, Gohlke A, Hauser A, Blume A, Winter R. 2007. Mechanism of islet amyloid polypeptide fibrillation at lipid interfaces studied by infrared reflection absorption spectroscopy. Biophys. J. 93:3132-3141 (Pubitemid 350097104)
103. Luca S, Yau WM, Leapman R, Tycko R. 2007. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 46:13505-13522 (Pubitemid 350209947)
104. Luheshi LM, Tartaglia GG, Brorsson AC, Pawar AP,Watson IE, et al. 2007. Systematic in vivo analysis of the intrinsic determinants of amyloid beta pathogenicity. PLoS Biol. 5:e290
105. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, et al. 2005. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA 102:17342-17347
106. Makin OS, Serpell LC. 2005. Structures for amyloid fibrils. FEBS J. 272:5950-5961
107. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, et al. 2008. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27:224-233
108. Marzban L, Park K, Verchere CB. 2003. Islet amyloid polypeptide and type 2 diabetes. Exp. Gerontol. 38:347-351 (Pubitemid 36379069)
109. Matsuzaki K. 1999. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1462:1-10
110. Matveyenko AV, Butler PC. 2006. Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 55:2106-2114
111. Matveyenko AV, Butler PC. 2006. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. Ilar J. 47:225-233
112. MirzabekovTA, Lin MC, Kagan BL. 1996. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271:1988-1992
113. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, et al. 2005. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435:773-778 (Pubitemid 40839722)
114. Nichols MR, Moss MA, Reed DK, Hoh JH, Rosenberry TL. 2005. Rapid assembly of amyloid-beta peptide at a liquid/liquid interface produces unstable beta-sheet fibers. Biochemistry 44:165-173
115. Nuscher B, Kamp F, Mehnert T, Odoy S, Haass C, et al. 2004. Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study. J. Biol. Chem. 279:21966-21975 (Pubitemid 38679387)
116. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL. 1995. Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. Am. J. Pathol. 147:609-616
117. Padrick SB, Miranker AD. 2001. Islet amyloid polypeptide: identification of long-range contacts and local order on the fibrillogenesis pathway. J. Mol. Biol. 308:783-794
118. Pastor MT, Kummerer N, Schubert V, Esteras-Chopo A, Dotti CG, et al. 2008. Amyloid toxicity is independent of polypeptide sequence, length and chirality. J. Mol. Biol. 375:695-707 (Pubitemid 350297277)
119. Petkova AT, Buntkowsky G, Dyda F, Leapman RD, Yau WM, Tycko R. 2004. Solid state NMR reveals a pH-dependent antiparallel beta-sheet registry in fibrils formed by a beta-amyloid peptide. J. Mol. Biol. 335:247-260 (Pubitemid 37494976)
120. Porat Y, Kolusheva S, Jelinek R, Gazit E. 2003. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42:10971-10977 (Pubitemid 37174388)
121. Powers ET, Powers DL. 2008. Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. Biophys. J. 94:379-391
122. Quist A, Doudevski I, Lin H, Azimova R, Ng D, et al. 2005. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. USA 102:10427-10432 (Pubitemid 41061570)
123. Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, et al. 2007. Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry 46:12451-12462 (Pubitemid 350027406)
124. Richards FM. 1958. On the enzymic activity of subtilisin-modified ribonuclease. Proc. Natl. Acad. Sci. USA 44:162-166
125. Riek R, Guntert P, Dobeli H,Wipf B,Wuthrich K. 2001.NMRstudies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, A beta(1-40)(ox) and A beta(1-42)(ox). Eur. J. Biochem. 268:5930-5936
126. Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. 2007. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56:65-71
127. Ruschak AM,Miranker AD. 2007. Fiber-dependent amyloid formation as catalysis of an existing reaction pathway. Proc. Natl. Acad. Sci. USA 104:12341-12346
128. Sachs JN, Engelman DM. 2006. Introduction to the membrane protein reviews: the interplay of structure, dynamics, and environment in membrane protein function. Annu. Rev. Biochem. 75:707-712
129. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, et al. 2007. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447:453-457 (Pubitemid 46816731)
130. Schladitz C, Vieira EP, Hermel H, Mohwald H. 1999. Amyloid-beta-sheet formation at the air-water interface. Biophys. J. 77:3305-3310
131. Schueler-Furman O, Wang C, Bradley P, Misura K, Baker D. 2005. Progress in modeling of protein structures and interactions. Science 310:638-642
132. Seelig J. 2004. Thermodynamics of lipid-peptide interactions. Biochim. Biophys. Acta 1666:40-50
133. Seilheimer B, Bohrmann B, Bondolfi L, Muller F, Stuber D, Dobeli H. 1997. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J. Struct. Biol. 119:59-71 (Pubitemid 27294721)
134. Sgourakis NG, Yan Y, McCallum SA,Wang C, Garcia AE. 2007. The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD/NMR study. J. Mol. Biol. 368:1448-1457 (Pubitemid 46617600)
135. Shao H, Jao S, Ma K, Zagorski MG. 1999. Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J. Mol. Biol. 285:755-773 (Pubitemid 29041806)
136. Shen Y, Joachimiak A, Rosner MR, Tang WJ. 2006. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443:870-874 (Pubitemid 44622699)
137. Sohl JL, Jaswal SS, Agard DA. 1998. Unfolded conformations of alpha-lytic protease are more stable than its native state. Nature 395:817-819
138. Soto C, Castano EM, Frangione B, Inestrosa NC. 1995. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem. 270:3063-3067
139. Sparr E, Engel MF, Sakharov DV, Sprong M, Jacobs J, et al. 2004. Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett. 577:117-120 (Pubitemid 39452370)
140. Srinivasan R, Marchant RE, Zagorski MG. 2004. ABri peptide associated with familial British dementia forms annular and ring-like protofibrillar structures. Amyloid 11:10-13 (Pubitemid 38680233)
141. Stefani M, Dobson CM. 2003. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81:678-699 (Pubitemid 37491594)
142. Sticht H, Bayer P,Willbold D, Dames S, Hilbich C, et al. 1995. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 233:293-298
143. Sugase K, Dyson HJ, Wright PE. 2007. Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 447:1021-1025
144. Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, et al. 2008. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213:114-121
145. Tartaglia GG, Pawar AP, Campioni S, Dobson CM, Chiti F, Vendruscolo M. 2008. Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 380:425-436
146. Thinakaran G, Koo EH. 2008. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283:29615-29619
147. Thundimadathil J, Roeske RW, Jiang HY, Guo L. 2005. Aggregation and porin-like channel activity of a beta sheet peptide. Biochemistry 44:10259-10270 (Pubitemid 41076821)
148. Tofaris GK, Spillantini MG. 2007. Physiological and pathological properties of alpha-synuclein. Cell Mol. Life Sci. 64:2194-2201
149. Turk J, Wolf BA, Lefkowith JB, Stump WT, McDaniel ML. 1986. Glucose-induced phospholipid hydrolysis in isolated pancreatic islets: quantitative effects on the phospholipid content of arachidonate and other fatty acids. Biochim. Biophys. Acta 879:399-409 (Pubitemid 17189928)
150. Tycko R. 2006. Molecular structure of amyloid fibrils: insights from solid-state NMR. Q. Rev. Biophys. 39:1-55 (Pubitemid 44566373)
151. Uversky VN, Oldfield CJ, Dunker AK. 2008. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys. 37:215-246
152. Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, et al. 2008. Soluble amyloid {beta} oligomers affect dielectric membrane properties by bilayer insertion and domain formation: Implications for cell toxicity. Biophys. J. 95:4845-4861
153. Wakamatsu K, Takeda A, Tachi T, Matsuzaki K. 2002. Dimer structure of magainin 2 bound to phospholipid vesicles. Biopolymers 64:314-327 (Pubitemid 34886978)
154. Westermark P, Engstrom U, Johnson KH,Westermark GT, Betsholtz C. 1990. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87:5036-5040 (Pubitemid 20224267)
155. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. 1987. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am. J. Pathol. 127:414-417 (Pubitemid 17089802)
156. Wetzel R, Shivaprasad S,Williams AD. 2007. Plasticity of amyloid fibrils. Biochemistry 46:1-10
157. White SH, von Heijne G. 2005. Transmembrane helices before, during, and after insertion. Curr. Opin. Struct. Biol. 15:378-386
158. Widenbrant MJ, Rajadas J, Sutardja C, Fuller GG. 2006. Lipid-induced beta-amyloid peptide assemblage fragmentation. Biophys. J. 91:4071-4080 (Pubitemid 44887267)
159. Williamson JA, Miranker AD. 2007. Direct detection of transient alpha-helical states in islet amyloid polypeptide. Protein Sci. 16:110-117
160. Wiltzius JJ, Sievers SA, Sawaya MR, Cascio D, Popov D, et al. 2008. Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin). Protein Sci. 17:1467-1474
161. Wong WP, Scott DW, Chuang CL, Zhang S, Liu H, et al. 2008. Spontaneous diabetes in hemizygous human amylin transgenic mice that developed neither islet amyloid nor peripheral insulin resistance. Diabetes 57:2737-2744
162. Wright CF, Teichmann SA, Clarke J, Dobson CM. 2005. The importance of sequence diversity in the aggregation and evolution of proteins. Nature 438:878-881 (Pubitemid 41753072)
163. Yagi H, Ban T, Morigaki K, Naiki H, Goto Y. 2007. Visualization and classification of amyloid beta supramolecular assemblies. Biochemistry 46:15009-15017 (Pubitemid 350308892)
164. Yan LM, Tatarek-Nossol M, Velkova A, Kazantzis A, Kapurniotu A. 2006. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. USA 103:2046-2051 (Pubitemid 43271620)
165. Yan LM, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A. 2007. IAPP mimic blocks Abeta cytotoxic self-assembly: Cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew. Chem. Int. Ed. Engl. 46:1246-1252 (Pubitemid 46981368)
166. YipCM, Darabie AA, McLaurin J. 2002. Abeta42-peptide assembly on lipid bilayers. J. Mol. Biol. 318:97-107
167. Yip CM, McLaurin J. 2001. Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys. J. 80:1359-1371 (Pubitemid 32182160)
168. Yoshiike Y, Akagi T, Takashima A. 2007. Surface structure of amyloid-beta fibrils contributes to cytotoxicity. Biochemistry 46:9805-9812 (Pubitemid 47328586)
169. Young A, Pittner R, Gedulin B, Vine W, Rink T. 1995. Amylin regulation of carbohydrate metabolism. Biochem. Soc. Trans. 23:325-331
170. Zhu M, Li J, Fink AL. 2003. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem. 278:40186-40197 (Pubitemid 37248587)